Astrazeneca Plc Adr Stock Buy Hold or Sell Recommendation
| AZN Stock | USD 64.26 1.06 1.68% |
Considering the 90-day investment horizon and your way above-average risk tolerance, our recommendation regarding AstraZeneca PLC ADR is 'Strong Sell'. The recommendation algorithm takes into account all of AstraZeneca PLC's available fundamental, technical, and predictive indicators you will find on this site.
Check out AstraZeneca PLC Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. In addition, we conduct extensive research on individual companies such as AstraZeneca and provide practical buy, sell, or hold advice based on investors' investing horizon and their risk tolerance towards AstraZeneca PLC ADR. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.
AstraZeneca |
Execute AstraZeneca PLC Buy or Sell Advice
The AstraZeneca recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on AstraZeneca PLC ADR. Macroaxis does not own or have any residual interests in AstraZeneca PLC ADR or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute AstraZeneca PLC's advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Very steady | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Moves indifferently to market moves | Details | |
Investor Sentiment | Impartial | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Very Strong | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
AstraZeneca PLC Trading Alerts and Improvement Suggestions
| AstraZeneca PLC ADR generated a negative expected return over the last 90 days | |
| AstraZeneca PLC ADR has 28.62 B in debt with debt to equity (D/E) ratio of 0.89, which is OK given its current industry classification. AstraZeneca PLC ADR has a current ratio of 0.79, suggesting that it has not enough short term capital to pay financial commitments when the payables are due. Note however, debt could still be an excellent tool for AstraZeneca to invest in growth at high rates of return. | |
| AstraZeneca PLC ADR has a very strong financial position based on the latest SEC filings | |
| Latest headline from investing.com: astrazeneca non-executive director buys company shares |
AstraZeneca PLC Returns Distribution Density
The distribution of AstraZeneca PLC's historical returns is an attempt to chart the uncertainty of AstraZeneca PLC's future price movements. The chart of the probability distribution of AstraZeneca PLC daily returns describes the distribution of returns around its average expected value. We use AstraZeneca PLC ADR price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of AstraZeneca PLC returns is essential to provide solid investment advice for AstraZeneca PLC.
| Mean Return | -0.44 | Value At Risk | -3.18 | Potential Upside | 0.98 | Standard Deviation | 1.43 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of AstraZeneca PLC historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
AstraZeneca Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument, such as AstraZeneca PLC, soars without any apparent reason. This usually happens because many institutional investors are aggressively trading AstraZeneca PLC ADR back and forth among themselves. Companies that invest excess capital in these types of assets may also be included in this term and can influence corporate governance by exercising voting rights in their investments.
| Shares | Fisher Asset Management, Llc | 2024-09-30 | 10.5 M | Atlantic Trust Group, Llc | 2024-06-30 | 9.2 M | Blackrock Inc | 2024-06-30 | 7 M | Capital World Investors | 2024-09-30 | 6.3 M | Gqg Partners Llc | 2024-09-30 | 5.5 M | Neuberger Berman Group Llc | 2024-06-30 | 5.4 M | Ing Investment Management Llc | 2024-06-30 | 5.3 M | Ameriprise Financial Inc | 2024-06-30 | 4.9 M | Dimensional Fund Advisors, Inc. | 2024-09-30 | 4.7 M | T. Rowe Price Associates, Inc. | 2024-06-30 | 64.9 M | Primecap Management Company | 2024-09-30 | 42 M |
AstraZeneca PLC Cash Flow Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change To Inventory | (316M) | (621M) | 1.6B | 3.9B | (669M) | (635.6M) | |
| Change In Cash | 552M | 2.3B | (1.5B) | (55M) | (346M) | (363.3M) | |
| Free Cash Flow | 509M | 2.2B | 3.8B | 7.2B | 6.6B | 6.9B | |
| Depreciation | 3.8B | 3.1B | 6.5B | 5.5B | 4.9B | 5.2B | |
| Other Non Cash Items | (2.0B) | (2.6B) | (2.3B) | (1.9B) | (2.4B) | (2.5B) | |
| Capital Expenditures | 2.5B | 2.6B | 2.2B | 2.6B | 3.8B | 1.9B | |
| Net Income | 1.5B | 3.9B | (265M) | 2.5B | 6.9B | 4.4B | |
| End Period Cash Flow | 5.2B | 7.5B | 6.0B | 6.0B | 5.6B | 4.1B | |
| Dividends Paid | 3.6B | 3.6B | 3.9B | 4.4B | 4.5B | 3.2B | |
| Investments | 125M | (285M) | 605M | (3.0B) | (3.2B) | (3.1B) | |
| Net Borrowings | (1.7B) | 1.4B | 7.7B | (1.4B) | (1.7B) | (1.6B) | |
| Change To Netincome | (816M) | (1.7B) | (272M) | (2.5B) | (2.2B) | (2.1B) |
AstraZeneca PLC Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to AstraZeneca PLC or Pharmaceuticals sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that AstraZeneca PLC's price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a AstraZeneca stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | -0.44 | |
β | Beta against Dow Jones | -0.14 | |
σ | Overall volatility | 1.46 | |
Ir | Information ratio | -0.37 |
AstraZeneca PLC Volatility Alert
AstraZeneca PLC ADR exhibits very low volatility with skewness of -2.09 and kurtosis of 6.78. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure AstraZeneca PLC's stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact AstraZeneca PLC's stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.AstraZeneca PLC Fundamentals Vs Peers
Comparing AstraZeneca PLC's fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze AstraZeneca PLC's direct or indirect competition across all of the common fundamentals between AstraZeneca PLC and the related equities. This way, we can detect undervalued stocks with similar characteristics as AstraZeneca PLC or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of AstraZeneca PLC's fundamental indicators could also be used in its relative valuation, which is a method of valuing AstraZeneca PLC by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare AstraZeneca PLC to competition |
| Fundamentals | AstraZeneca PLC | Peer Average |
| Return On Equity | 0.17 | -0.31 |
| Return On Asset | 0.085 | -0.14 |
| Profit Margin | 0.13 % | (1.27) % |
| Operating Margin | 0.20 % | (5.51) % |
| Current Valuation | 222.82 B | 16.62 B |
| Shares Outstanding | 3.1 B | 571.82 M |
| Shares Owned By Institutions | 16.75 % | 39.21 % |
| Number Of Shares Shorted | 4.63 M | 4.71 M |
| Price To Earning | 103.39 X | 28.72 X |
| Price To Book | 4.81 X | 9.51 X |
| Price To Sales | 3.85 X | 11.42 X |
| Revenue | 45.81 B | 9.43 B |
| Gross Profit | 35.73 B | 27.38 B |
| EBITDA | 12.98 B | 3.9 B |
| Net Income | 6.9 B | 570.98 M |
| Cash And Equivalents | 4.52 B | 2.7 B |
| Cash Per Share | 1.46 X | 5.01 X |
| Total Debt | 28.62 B | 5.32 B |
| Debt To Equity | 0.89 % | 48.70 % |
| Current Ratio | 0.81 X | 2.16 X |
| Book Value Per Share | 26.27 X | 1.93 K |
| Cash Flow From Operations | 10.35 B | 971.22 M |
| Short Ratio | 1.30 X | 4.00 X |
| Earnings Per Share | 2.07 X | 3.12 X |
| Price To Earnings To Growth | 0.68 X | 4.89 X |
| Target Price | 88.27 | |
| Number Of Employees | 89.9 K | 18.84 K |
| Beta | 0.18 | -0.15 |
| Market Capitalization | 197.02 B | 19.03 B |
| Total Asset | 101.12 B | 29.47 B |
| Retained Earnings | 4.52 B | 9.33 B |
| Working Capital | (5.49 B) | 1.48 B |
| Current Asset | 16.01 B | 9.34 B |
AstraZeneca PLC Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as AstraZeneca . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
| Accumulation Distribution | 109006.0 | |||
| Daily Balance Of Power | 1.308642 | |||
| Rate Of Daily Change | 1.02 | |||
| Day Median Price | 63.94 | |||
| Day Typical Price | 64.04 | |||
| Price Action Indicator | 0.86 | |||
| Period Momentum Indicator | 1.06 | |||
| Relative Strength Index | 26.19 |
About AstraZeneca PLC Buy or Sell Advice
When is the right time to buy or sell AstraZeneca PLC ADR? Buying financial instruments such as AstraZeneca Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having AstraZeneca PLC in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Real Estate Thematic Idea Now
Real Estate
Publicly traded companies that are involved in real estate development, property maintenance and management of real estate investment trusts (REIT) funds. The Real Estate theme has 38 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Real Estate Theme or any other thematic opportunities.
| View All Next | Launch |
Check out AstraZeneca PLC Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. You can also try the Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of AstraZeneca PLC. If investors know AstraZeneca will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about AstraZeneca PLC listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.034 | Dividend Share 2.97 | Earnings Share 2.07 | Revenue Per Share 2.7424 | Quarterly Revenue Growth 0.18 |
The market value of AstraZeneca PLC ADR is measured differently than its book value, which is the value of AstraZeneca that is recorded on the company's balance sheet. Investors also form their own opinion of AstraZeneca PLC's value that differs from its market value or its book value, called intrinsic value, which is AstraZeneca PLC's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because AstraZeneca PLC's market value can be influenced by many factors that don't directly affect AstraZeneca PLC's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between AstraZeneca PLC's value and its price as these two are different measures arrived at by different means. Investors typically determine if AstraZeneca PLC is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, AstraZeneca PLC's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.